Living with Chronic Disease: Measuring Important Patient-Reported Outcomes

Dr Paul Kamudoni PhD is a research fellow with the Institute of Medicines Development based in Cardiff, UK. Paul has a background in pharmacoeconomics and clinical outcomes measurement. His work is focused on developing new patient-reported outcome (PRO) measures as well as overseeing design and data analysis of PRO aspects in clinical studies, for pharmaceutical clients. Among others, his research interests include methodological issues in the integration of electronic health records with prospective PRO assessments, the use of item response theory in PRO measure development, the design and development of disease-specific utility measures. Dr Nutjaree Pratheepawanit Johns PhD PharmD is currently an Associate Professor and Director of Melatonin Research Group, Faculty of Pharmaceutical Sciences, Khon Kaen University, Thailand. She has held a number of academic positions both in Thailand and abroad, including a 1-year fellowship at the International Fellows Program on Human Research Ethics at the Western Institutional Review Board (WIRB) (Olympia, WA, USA). Dr. Johns has an education and background in cancer care and quality of life (QoL) research, and practices in collaboration with many cancer centers in Northeast of Thailand. She has developed and tested many QoL measures and been involved in various projects for cross-cultural adaptation of QoL and PRO measures. Dr. Johns is also a principal investigator in many clinical trials to investigate the effects of disease or interventions on the QoL of cancer patients. She is a member of a number of research committees and has been a recipient of a number of prestigious awards including Scholarship for Developing Country, International Society for Quality of Life Research and the Doyle Prize: Postgraduate section, Palliative Medicine Journal.Sam Salek PhD RPh FFPM MRPSGB MCMS FESCP is Professor of Pharmacoepidemiology at the University of Hertfordshire, Hatfield, visiting Professor at the Estate of Hessen, Germany, and Director of the Institute for Medicines Development, Cardiff, UK. Professor Salek's research focuses mainly on four areas: development and application of patient-reported outcome measures; drug safety evaluation and pharmacovigilance; pharmacoeconomics and economic evaluation of healthcare; and pharmaceutical regulation & medicines development in the mature and emerging markets. He has published 22 books and 600+ journal articles and abstracts. Professor Salek is a member of five Editorial Boards and an active member of several societies.